STOCK TITAN

Verano Announces Second Quarter 2022 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) reported its Q2 2022 financial results, showcasing a 12% revenue increase to $224 million compared to Q2 2021. Gross profit rose to $98 million, representing 44% of revenue. Despite a net loss of $(10) million, an improvement from $(30) million last year, unadjusted EBITDA stood at $48 million. Operationally, Verano exceeded 100 dispensaries and celebrated adult-use sales in New Jersey. The company also invested in mobile applications and new product lines, aiming for sustainable growth.

Positive
  • Q2 2022 revenue increased 12% to $224 million.
  • Gross profit rose to $98 million, 44% of revenue.
  • Net loss improved to $(10) million from $(30) million.
  • Unadjusted EBITDA reached $48 million, 22% of revenue.
  • Exceeding 100-dispensary milestone with multiple new openings.
Negative
  • SG&A increased to $100 million, 45% of revenue.
  • Working capital deficit of $(299) million.
  • Total debt of $403 million.

CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the second quarter ended June 30, 2022 (“Q2 2022"), which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Second quarter 2021 comparable numbers were also prepared in accordance with U.S. GAAP. All financial results for the second quarter ended June 30, 2022 and related comparisons to prior periods included in this release are preliminary, have not been reviewed or audited, are based on the Company's estimates and were prepared prior to the completion of the Company's financial statement close process.

2022 Second Quarter Financial Highlights

  • Q2 2022 revenue increased 12% to $224 million compared to the second quarter 2021.
  • Q2 2022 gross profit was $98 million or 44% of revenue, compared to $69 million or 35% of revenue in the second quarter 2021.
  • Q2 2022 SG&A was $100 million or 45% of revenue, compared to $70 million or 35% of revenue in the second quarter 2021.
  • Q2 2022 net loss was $(10) million, compared to a loss of $(30) million in the second quarter 2021.
  • Q2 2022 EBITDA on an unadjusted basis was $48 million or 22% of revenue, and Adjusted EBITDA1 was $76 million or 34% of revenue.
  • Cash flow from operations for the six months ended June 30, 2022 was $44 million.

2022 Second Quarter Operational Highlights

  • On April 21, 2022, Verano welcomed New Jersey Governor Phil Murphy at Zen Leaf Elizabeth to celebrate the commencement of adult use sales in the state, and also launched adult use sales at the Company’s Zen Leaf Lawrence Township dispensary.
  • Exceeded 100-dispensary milestone by expanding the Company’s retail footprint with new store openings that include:
    • five new MÜV dispensaries located in Marco Island, Hobe Sound, Fort Myers Beach, Ocala, and Winter Haven, FL. 
    • two new Zen Leaf locations in Westover, WV and Wynnewood, PA.
  • Announced exclusive partnership with The Weldon Project’s Mission Green to advance cannabis clemency and advocacy initiatives.
  • Relocated Zen Leaf dispensaries in Canton, OH and Phoenix, AZ to optimize store locations and amenities.
  • Launched mobile applications and exclusive rewards programs for Verano’s flagship Zen Leaf and MÜV dispensaries.

_________________________

1 Adjusted EBITDA is a non-GAAP financial measure. It is derived from EBITDA, another non-GAAP financial measure, both of which are defined in this news release in the section below titled “Non-GAAP Financial Measures.”  The most comparable U.S. GAAP financial measure to Adjusted EBITDA and EBITDA is net income. The reconciliations of Adjusted EBITDA and EBITDA to U.S. GAAP net income is set forth below in the tables included in this news release.

Subsequent Operational Highlights

  • Surpassed 50-dispensary retail footprint milestone for MÜV in Florida, bringing the total state footprint to 55.
  • Opened new Zen Leaf dispensary in Wheeling, WV; relocated Zen Leaf Jessup to Elkridge in Maryland to optimized location and retail space; maximized New Jersey footprint with the commencement of adult use sales at Zen Leaf Neptune on the Jersey Shore.
  • Launched Verano signature flower branded products in four new core markets – Arizona, Florida, Massachusetts and Pennsylvania; Verano signature flower branded products are now distributed to more than 500 dispensaries across nine states, including more than 100 of the Company’s retail locations.
  • Announced the upcoming launch of Savvy in September 2022, a new brand featuring larger-format cannabis products that caters to more value-oriented patients and consumers, across seven core markets.
  • Active operations span 13 states, comprised of 109 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity.

Management Commentary
“I am very proud of our performance this quarter alongside the strategic investments we made to ensure our high operational standards touch every part of our business,” said George Archos, Verano Founder and Chief Executive Officer. “Despite ongoing macroeconomic headwinds, we achieved a number of wins throughout the quarter, including the successful launch of adult use sales in New Jersey, exceeding a milestone of operating more than 100 dispensaries following the opening of seven new stores in Florida, West Virginia and Pennsylvania, announced a partnership with Mission Green to advance cannabis clemency and social equity initiatives, and launched mobile applications and rewards programs for our flagship Zen Leaf and MÜV dispensaries. I am proud of what we have accomplished since going public last year and remain confident that the strategy and plans we have in place will drive long term, sustainable growth for Verano.”

Balance Sheet and Liquidity
As of June 30, 2022, the Company’s current assets were $288 million, including cash and cash equivalents of $93 million. The Company had working capital (deficit) of $(299) million and total debt, net of issuance costs, of $403 million.

The Company’s total Class A subordinate voting shares outstanding, including Class B proportionate voting shares on an as-converted to Class A subordinate voting share basis, was 330,818,664 as of June 30, 2022.

Non-GAAP Financial Measures
Verano uses non-GAAP financial information to evaluate the performance of the Company. The terms “EBIT,” “EBITDA,” and “Adjusted EBITDA” do not have any standardized meaning prescribed within U.S. GAAP and therefore may not be comparable to similar measures presented by other companies. Accordingly, this non-GAAP financial information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with U.S. GAAP.

The Company calculates EBIT as net earnings from operations before interest expense and tax expenses, EBITDA as net earnings from operations before interest expense, tax expense, depreciation, and amortization and Adjusted EBITDA as EBITDA as adjusted for one-time expenses related to other expenses, employee stock compensation, gain from investment in associates, acquisition, transaction and other non-operating costs and acquisition adjustments and other income (expense), net. The calculations of the non-GAAP financial measures used in this news release and the reconciliations to the most comparable U.S. GAAP financial numbers are included in the tables below. 

Management believes that this non-GAAP financial information is useful as a supplement to comparable U.S. GAAP financial information. Management reviews these non-GAAP financial measures on a regular basis and uses them, together with financial measures included in the Company’s financial statements, to evaluate and manage the performance of the Company’s operations. These measures should be evaluated only in conjunction with the comparable U.S. GAAP financial numbers reported by the Company.

Conference Call and Webcast
A conference call and audio webcast with analysts and investors will be held on August 16, 2022 at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results and answer investor and participant questions.

  • Investors and participants can register in advance for the call by visiting: https://conferencingportals.com/event/QNkIOmXU
  • After registering, instructions will be shared on how to join the call for those who wish to dial in.
  • On August 16, 2022, the live webcast can be accessed via the following link: https://events.q4inc.com/attendee/764015566
  • The live and archived webcast will be available on the Events and Presentations page of the Company’s investor relations website at investors.verano.com .

About Verano
Verano is a leading, vertically integrated, multi-state cannabis operator in the U.S., devoted to the ongoing improvement of communal wellness by providing responsible access to regulated cannabis products. With a mission to address vital health and wellness needs, Verano produces a comprehensive suite of premium, innovative cannabis products sold under its trusted portfolio of consumer brands, including Verano, Avexia, Encore, and MÜV. Verano’s portfolio encompasses 14 U.S. states, with active operations in 13, including 13 cultivation and processing facilities comprising over 1,000,000 square feet of cultivation capacity. Verano designs, builds, and operates dispensaries under retail brands including Zen Leaf and MÜV, delivering a superior cannabis shopping experience in both medical and adult-use markets. Learn more at www.verano.com.

Contacts:
Investors
Verano
Julianna Paterra, CFA
Director, Investor Relations
julianna.paterra@verano.com

Media
Verano
Steve Mazeika
Director, Communications
steve.mazeika@verano.com
312-348-4430

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s registration statement on Form 10, as amended, and quarterly reports on Form 10-Q filed with the U.S. Securities and Exchange Commission at www.sec.gov. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Financial Information Tables

The following tables present the reconciliations of the non-GAAP financial measures to the respective most directly comparable GAAP financial measures for the three and six months ended June 30, 2022 and 2021.


VERANO HOLDINGS CORP.
Highlights from Unaudited Consolidated Statements of Operations
($ in Thousands except share and per share amounts)

  Three Months Ended June 30,  Six Months Ended June 30, 
  2022  2021  2022  2021 
Revenue $223,662  $199,066  $425,897  $319,961 
Cost of Sales  125,547   129,856   229,165   196,461 
Gross Profit  98,115   69,210   196,732   123,500 
Gross Profit %  43.9%  34.8%  46.2%  38.6%
Expenses:                
Selling, General, and Administrative  100,263   70,013   189,824   112,679 
Total Expenses  100,263   70,013   189,824   112,679 
Income (Loss) from Investments in Associates  (144)  645   1,860   1,448 
Income (Loss) from Operations  (2,292)  (158)  8,768   12,269 
Other Income (Expense):                
Loss on Disposal of Property, Plant and Equipment  (203)  (429)  (1,192)  (429)
Gain (Loss) on Deconsolidation  (73)     9,485    
Gain (Loss) on Previously Held Equity Interest  (171)     13,928    
Interest Expense, net  (11,624)  (5,434)  (22,295)  (7,201)
Other Income (Expense), net  15,619   (131)  18,153   (997)
Total Other Income (Expense)  3,548   (5,994)  18,079   (8,627)
Net Income (Loss) Before Provision for Income Taxes and Non-Controlling Interest  1,256   (6,152)  26,847   3,642 
Provision For Income Taxes  (11,103)  (23,438)  (36,617)  (39,852)
Net Income Attributable To Non-Controlling Interest     98   291   1,364 
Net Loss Attributable to Verano Holdings Corp.  (9,847)  (29,688)  (10,061)  (37,574)
Net Loss per share - basic  (0.03)  (0.10)  (0.03)  (0.14)
Net Loss per share - diluted  (0.03)  (0.10)  (0.03)  (0.14)
Weighted average number of shares outstanding - basic  328,519,193   300,715,671   327,402,503   265,842,657 
Weighted average number of shares outstanding - diluted  328,519,193   300,715,671   327,402,503   265,842,657 


VERANO HOLDINGS CORP.

Highlights from Condensed Consolidated Balance Sheets
($ in Thousands)

  June 30,  December 31, 
  2022  2021 
  (Unaudited)  (As Restated) 
Cash and Cash Equivalents $92,833  $99,118 
Other Current Assets  195,123   177,926 
Property and Equipment, Net  515,698   452,232 
Intangible Assets, Net  1,343,371   1,379,913 
Goodwill  376,637   368,130 
Other Long-Term Assets  81,308   71,336 
Total Assets $2,604,970  $2,548,655 
         
Total Current Liabilities $586,777  $470,516 
Total Long-Term Liabilities  469,468   596,333 
Total Shareholders' Equity  1,548,725   1,480,530 
Non-controlling Interest     1,276 
Total Liabilities and Shareholders' Equity $2,604,970  $2,548,655 


VERANO HOLDINGS CORP.

Unaudited Reconciliation of Net Loss to EBITDA (Non-GAAP)

($ in thousands) Three Months Ended
June 30,
  Six Months Ended
June 30,
 
  2022  2021  2022  2021 
Net Loss Attributable to Verano Holdings Corp. $(9,847) $(29,688) $(10,061) $(37,574)
Interest Expense, net  11,624   5,434   22,295   7,201 
Income Tax Expense  11,103   23,438   36,617   39,852 
Depreciation and Amortization - COGS  19,089   13,963   38,814   22,282 
Depreciation and Amortization - SG&A  16,388   10,311   31,097   13,775 
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)  48,357   23,458   118,762   45,536 


VERANO HOLDINGS CORP.

Unaudited Reconciliation of Net Loss to EBIT (Non-GAAP) and Adjusted EBITDA (Non-GAAP)

($ in thousands) Three Months Ended June 30,  Six Months Ended June 30, 
  2022  2021  2022  2021 
Net Loss Attributable to Verano Holdings Corp. $(9,847) $(29,688) $(10,061) $(37,574)
Interest Expense, Net  11,624   5,434   22,295   7,201 
Income Tax Expense  11,103   23,438   36,617   39,852 
Earnings Before Interest and Taxes (EBIT) $12,880  $(816) $48,851  $9,479 
                 
COGS Add-backs:                
Depreciation and Amortization  19,089   13,963   38,814   22,282 
Acquisition, Transaction and Other Non-operating Costs  15,385   35,167   19,998   53,804 
Employee Stock Compensation  2,976      4,027    
                 
SG&A Add-backs:                
Depreciation and Amortization  16,388   10,311   31,097   13,775 
Acquisition, Transaction and Other Non-operating Costs  10,720   10,038   22,972   23,316 
Employee Stock Compensation  10,515   12,580   20,377   18,333 
                 
Acquisition Adjustments and Other Income (Expense), net  (12,428)  (635)  (23,397)  421 
                 
Adjusted EBITDA $75,526  $80,608  $162,738  $141,409 


FAQ

What were Verano's Q2 2022 financial results for revenue and profit?

Verano reported Q2 2022 revenue of $224 million, a 12% increase from the previous year, with a gross profit of $98 million.

How did Verano's net loss change in Q2 2022?

Verano's net loss in Q2 2022 was $(10) million, compared to a loss of $(30) million in Q2 2021.

What operational milestones did Verano achieve in Q2 2022?

Verano opened multiple dispensaries, exceeding a total of 100 locations, and launched adult use sales in New Jersey.

What is Verano's current debt situation as of June 30, 2022?

As of June 30, 2022, Verano had a total debt of $403 million and a working capital deficit of $(299) million.

What is the outlook for Verano regarding new product launches?

Verano is set to launch the Savvy brand in September 2022, focusing on value-oriented cannabis products.

VERANO HLDGS CORP

OTC:VRNOF

VRNOF Rankings

VRNOF Latest News

VRNOF Stock Data

610.70M
302.30M
15.59%
10.6%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Chicago